2-6-20151 Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June 2 2008, McCormick.

Slides:



Advertisements
Similar presentations
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Advertisements

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Modified Megestrol The Clinical Trials by : Carolina R. Akib
HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.
M.R. CHRISTIAENS MD PHD MULTIDISCIPLINAIR BORSTCENTRUM LEUVEN Metastatic Breast Cancer: A Surgical Challenge.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a.
Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,
Lymphadenectomy in Epithelial Ovarian Cancer
Supplemental Figures Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cristina Cadenas 1*, Leonie van de Sandt.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.
Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority.
Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
1 ASCO Annual Meeting 2013 Poster presentation January 2013.
DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Evidence Based Approach 5-Year Survival Rate for Breast Cancer Stage IV is 14% 2 to 5 percent become long-term survivors, possibly cured of their disease.
Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC randomised trial From.
Should liver metastases of breast cancer be biopsied to improve treatment choice? M. A. Locatelli, G. Curigliano, L. Fumagalli, V. Bagnardi, G. Aurilio,
Mamoun A. Rahman Surgical SHO Mr Osborne’s team. Introduction Blood transfusion: -Preoperative ( elective) -Intra/postoperative ( urgent) Blood transfusion.
Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Role of Radiation Therapy in Brain metastasis Bongkot Supawongwattana, M.D. Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang.
Indivisualized approach for brain surveillance in high-risk breast cancer patients Soohyeon Lee Yonsei Cancer Center Severance Hospital Division of Medical.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Surgery for Metastatic Brain Tumor from Breast Cancer
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
Beyond breast specific—Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome Gaia Griguolo DiSCOG-University.
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
Brain imaging prior to lung cancer resection
Challenges for the treatment of breast cancer
Prognostic significance of tumor subtypes in male breast cancer:
Results of Definitive Radiotherapy in Anal Canal Carcinoma
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Compassionate People World Class Care
Dr T P E Wells 13 July 2018 Breast SSG Bath
Untch M et al. Proc SABCS 2010;Abstract P
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Published online September 20, 2017 by JAMA Surgery
GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR
Presentation transcript:

Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June , McCormick Place Chicago, Abstract #1076 Michael Knauer 1, Andrea Rottenfusser 2, Rupert Bartsch 3, Karin Dieckmann 2, Catharina Wenzel 3, Sabine Fromm 2, Helmut Eiter 4, Guenther G Steger 3, Christoph C Zielinski 3, and Alexander de Vries 4 1 Department of Surgery, Academic Teaching Hospital Feldkirch, 2 Department of Radiotherapy, Medical University of Vienna, 3 First Department of Medicine and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, 4 Department of Radiotherapy, Academic Teaching Hospital Feldkirch, Austria

Abstract Background: Different groups reported an increased incidence of brain metastases (BM) in patients (pts) with Her2-positive breast cancer (BC). Usually, this is attributed to prolonged survival due to trastuzumab (T), in association with the inability of antibodies to pass the blood-brain-barrier. Furthermore, based on preclinical data, it was suggested that Her2- positive BC had an increased affinity to brain tissue. We investigated factors potentially associated with shorter time to development of BM. Patients and Methods: 194 pts with BM from BC were identified at two Austrian centres. All received whole brain radiotherapy (WBRT) of 30 Gy. Data concerning epidemiology, histology, and outcome, is available. A multivariate analysis (Cox regression) was performed to identify factors significantly associated with early development of BM. Results: Median age was 55 years, and time to development of BM was 29 months (m), range 2 – 254 m, 95% CI Overall survival following WBRT was 7 m. The following factors predicted shorter time to development of BM: negative endocrine receptor status (p=0.026), Her2-positive disease (p=0.003), stage IV disease at first presentation (p<0.001), and lung metastases (p=0.043). Discussion: Risk factors associated with increased incidence of BM have already been described. Our data show that Her2– positive BC is significantly associated with early development of BM, while no influence of T was observed. These results underline preclinical data suggesting a higher affinity of Her2-positive BC to the brain. T, on the other hand, had no prophylactic effect. Therefore, trials evaluating the combination of T with substances able to penetrate into the brain are warranted.

Background Since the introduction of trastuzumab in the nineties, different centres reported an increase incidence of brain metastases (BM) in patients with Her2-positive breast cancer (BC)1,2 While risk factors associated with development of brain metastases are well defined, little is known about patients at high risk for early development of brain disease

Her2 and brain metastasis The increased incidence of brain metastases in Her2 positive tumours is usually attributed to trastuzumab, as the introduction of this compound lead to prolonged survival, in association with the inability of antibodies to pass an intact blood-brain-barrier As Her2 may also cause increased tumour angiogenesis via induction of HIF1α, it was recently suggested that the Her2-positive BC phenotype had a higher affinity to brain tissue

Patients and Methods A total number of 194 patients treated for BM from breast cancer were identified at two Austrian centres All had received whole brain radiotherapy (WBRT) of 30 Gy with or without boost irradiation or surgical resection A multivariate analysis (Cox regression model) was performed to identify factors associated with shorter time to development of brain metastases The following variables were included: age at primary diagnosis of BC (≤ 35 years vs. > 35 years), grading (grade 1, 2 vs. grade 3), ER/PgR-status (positive vs. negative), Her2-status, tumour stage at diagnosis (localized vs. stage IV), lung metastases, liver metastases, trastuzumab (T) before diagnosis of BM

Patient characteristics CentresMedical University of Vienna General Hospital Feldkirch Number194 patients from 2004 until 2007 Age at diagnosis of BMmedian 55 years range years Pts ≤ 35 years at diagnosis13 pts Histological subtypeductal 114 pts lobular 80 pts Grading G1/2 70 pts G3 98 pts ER/PgR positive 58 pts / 38 pts Her2-positive53 pts Primary metastatic disease33 pts Lung / Liver metastases72 pts / 72 pts

Results Median age at WBRT was 55 years, range 28 – 81 years 81 pts received further local therapy (boost irradiation or neurosurgical resection) Time to development of BM was 29 months, range 2 – 254 months, 95% CI Overall survival following WBRT was 7 months, range 1 – 83 months, 95% CI

Survival after development of BM

Multivariate analysis Age at primary diagnosis of BCn.s. Grading n.s. ER/PgR-status p=0.026 Her2-status p=0.003 Tumour stage at diagnosis p<0.001 Lung metastasesp=0.043 Liver metastases n.s. Trastuzmab before diagnosis of BMn.s.

Discussion and Summary Her2–positive BC is significantly associated with shorter time to development of BM No influence of trastuzumab was observed Therefore, trials evaluating the combination of trastuzumab with substances able to penetrate into the brain are warranted

References (1) Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972–2977 (2) Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91(4):639–643